摘要
目的 观察泛昔洛韦对HBV慢性感染抗病毒的治疗效果。方法 慢性乙型肝炎患者 89例 ,采用随机对照分组 ,和单用泛昔洛韦治疗组 32例 ,和单用α 干扰素 2 9例和单用拉米夫定 2 8例两个对照组 ,对比观察三组抗病毒治疗效果。结果 治疗组泛昔洛韦血清HBVDNA阴转率 4 0 .6 2 % (13 32 ) ,HBeAg阴转率 2 1.88% (7 32 ) ;对照组α 干扰素血清HBVDNA阴转率 37.93% (11 2 9) ,HBeAg阴转率4 1 38% (12 2 9) ;拉米夫定血清HBVDNA阴转率 6 7.90 % (19 2 8) ,HBeAg阴转率 2 1.4 3% (6 2 8)。治疗组HBVDNA阴转时间最短 1个月 ,最长 3个月 ,平均 1.3个月 ,无 1例出现严重不良反应。结论 泛昔洛韦治疗HBV慢性感染安全有效。
Objective To evaluate the effects of famciclovir treatment of patients with chronic hepatitis B virus (HBV) infection.Methods Eighty nine patients with chronic HBV infection were randomly divided into three groups. Thirty two patients were treated with famciclovir, 29 patients and 28 patients with chronic HBV infection were treated with interferon (IFN) alpha and lamivudine, respectively, as the control. Results The serum HBV DNA became negative after treatment in 40.62% (13/32) of patients treated with famciclovir, 37 93% (11/29) of patients treated with IFN alpha, and 67.90% (19/28) of patients treated with lamivudine. The rate of serum HBeAg loss for the three groups were 21.88% (7/32), 41.38% (12/29) and 21.43% (6/28) , respectively. The average time for patients to become serum HBV DNA negative was 1.3 months. Conclusion Famciclovir is an effective and safe nucleoside drug for the treatment of patients with chronic HBV infection.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2002年第4期390-391,共2页
Chinese Journal of Experimental and Clinical Virology
